HH and PD-1 inhibitors: watch for adverse events
By John Jesitus | Reviewed by Todd Schlesinger, MD The efficacy of newer medications including inhibitors of hedgehog (HH) and programmed death-1 (PD-1) signaling carries the caveat that prescribers must monitor for multi-systemic adverse events (AEs), which may be severe. Additional considerations with both drug categories include resistance and, for HH inhibitors (HHIs), potential drug […]